Schering aquires CIS bio international
CIS specialises in the development, production, marketing and distribution of radiopharmaceuticals for diagnosis and therapy. CIS also has a strong portofolio and reputation in the in-vitro diagnostic field, radioimmunology and Drug screening.
"The acquisition and integration of CIS into Schering AG's worldwide activities supports Schering AG's strategy to become a substantial player in the global radiopharmaceutical market," said Hans-Michael Rook, Head of Diagnostics and Radiopharmaceuticals at Schering AG. "The area of oncological radiopharmaceuticals presents a particularly attractive opportunity given Schering AG's existing expertise in oncology and the potential for synergies between its diagnostics and therapeutics businesses".
Organizations
Other news from the department business & finance
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.